3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
5
Myeloid
4
Lymphoid
4
Plasma cell
2
Other solid neoplasm
2
Gynecologic
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Genitourinary
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Ovarian Neoplasms
2
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Paclitaxel
143
pembrolizumab
121
Carboplatin
109
Bevacizumab
93
Cisplatin
69
Specimen Handling
62
olaparib
51
Magnetic Resonance Spectroscopy
51
Gemcitabine
41
Nivolumab
36
Biopsy
36
liposomal doxorubicin
34
Taxes
33
Cyclophosphamide
31
Blood Specimen Collection
31
niraparib
28
lenvatinib
26
Letrozole
26
Doxorubicin
26
Topotecan
25
Drug Therapy
25
Immunoglobulin G
23
Brachytherapy
22
fludarabine
21
atezolizumab
21
Radiotherapy
21
Disulfides
21
durvalumab
20
dostarlimab
19
Surveys and Questionnaires
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Blood Component Removal
×
Gynecologic
×
1 year
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled
NCT05920798
2026-04-06
FRAPPE
Mayo Clinic
Phase 1/2
Recruiting
40 enrolled